Genmab — November 2017
-
-
this highlights the focus on measuring minimal residual disease (MRD) status -in the CANDOR study, Amgen /Janssen, comparing Kyprolis
(carfilzomib), Darzalex (daratumumab), and dexamethasone : http://www.businesswire.com/news/home/20171106005325/en/Adaptive-Biotechnologies-Announces-Collaboration-Amgen-Advance-Clinical -
@sukkeralf : Tjaah...., Novod nu 1480 og aktuel kurs 1227, lyder jo helt "hysterisk" hvis det skulle være (en af) årsagerne....
-
-
In the Netherlands, the National Health Care Institute determines and advises on which types of health care are included in the basic care package and which are not. There was an advisory committee meeting oktober 27 on daratumumab. This was an open meeting, but only today they published their advice to their board: (in dutch) https://www.zorginstituutnederland.nl/publicaties/adviezen/2017/10/27/advies-acp-aan-de-rvb-over-de-beoordeling-van-daratumumab-darzalex-bij-multipel-myeloom
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind